The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
883
November 13, 1992
View Complete Issue         Table of Contents 2019 
Teniposide for Acute Lymphoblastic Leukemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Teniposide for Acute Lymphoblastic Leukemia
November 13, 1992 (Issue: 883)
Teniposide (ten i poe' side; VM 26; Vumon - Bristol), an anticancer drug that has been under investigation in the USA for 20 years, has now been approved for use in combination induction treatment of refractory acute lymphoblastic leukemia (ALL) in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Teniposide for Acute Lymphoblastic Leukemia
Article code: 883b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.